Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.64%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
Follow TMO
Alert me
Thermo Fisher Scientific Inc. (TMO) EV/EBITDA
As of 5 November 2026, Thermo Fisher Scientific Inc. (TMO) trades at a EV/EBITDA of 24.6×. Over the past ten years it has ranged from 14.0× (September 2015) to 27.9× (September 2020); the current reading is higher than 96% of that period. That is in line with the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 23.2× | 9.05% |
| FY2024 | 21.3× | (6.39%) |
| FY2023 | 22.7× | 12.78% |
| FY2022 | 20.1× | (12.54%) |
| FY2021 | 23.0× | 20.65% |
| FY2020 | 19.1× | (9.28%) |
| FY2019 | 21.0× | 20.61% |
| FY2018 | 17.5× | (7.07%) |
| FY2017 | 18.8× | 10.99% |
| FY2016 | 16.9× | 0.77% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 24.4× | 22.52% |
| Jun 2026 | 19.9× | (2.81%) |
| Mar 2026 | 20.5× | (11.54%) |
| Dec 2025 | 23.2× | 12.92% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| IQV IQVIA Holdings Inc. compare | 16.5× |
| DHR Danaher Corporation compare | 22.3× |
| TMO Thermo Fisher Scientific Inc. | 24.6× |
| ILMN Illumina, Inc. compare | 26.4× |
| A Agilent Technologies, Inc. compare | 26.4× |
| MTD Mettler-Toledo International, Inc. compare | 27.4× |
| IDXX IDEXX Laboratories, Inc. compare | 31.8× |
| WAT Waters Corporation compare | 51.9× |
| Diagnostics & Research industry median | 23.4× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on TMO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement